Agilent's Cost-Cutting to Help in 2013

Zacks

Agilent Technologies’ (A) fiscal third-quarter earnings per share of 68 cents beat the Zacks Consensus Estimate by 6 cents, or 9.6%.

Revenue

Agilent’s revenue of 1.65 billion was down 4.6% sequentially and 4.1% year over year.

The Asia/Pacific remained the biggest contributor to revenues with a 39% share. The Americas was next with 35%, followed by Europe, which accounted for the balance. While all three regions declined sequentially, it was most pronounced in the Americas (down 5.6%), followed by the Asia/Pacific, which declined 4.9% and Europe, which declined 2.8%. The Americas dropped 14.3% from the year-ago quarter, with the Asia/Pacific coming in flattish and Europe up 6.0%.

The most significant declines were in the aerospace/defense and communications markets with pharma/biotech and petro/chemical testing being the only end markets to have seen sequential growth. However, food and aerospace/defense also grew from last year.

Revenue by Segment

Agilent reports results under four segments—Chemical Analysis, Life Sciences, Electronic Measurement and Diagnostics & Genomics.

In the last quarter, Agilent’s Electronic Measurement segment remained the largest contributor, accounting for 42% of its revenue. The segment was down 7.8% sequentially and 17.0% year over year indicating continued softness in key areas.

The significant weakness in the last quarter was on account of the loss of a major handset manufacturing test customer. Still-modest capacity additions and over capacity conditions (in some cases) in the semiconductor equipment market, the secular decline in the PC market and the negative macro impact on the industrial market are the main reasons for this softness.

Agilent’s Life Sciences segment generated 24% of revenues, which was down 1.0% sequentially and up 2.6% year over year. This sequential decline was attributable to the residual negative impact of government spending decisions, which has impacted the academia and government business. Management said that stronger consumables, services, support and informatics sales resulted in the year-over-year increase.

Technology upgrades on the pharma side remained a positive for both the sequential and year-on-year comparisons. Additionally, LC/LCMS product introductions continued.

The Chemical Analysis segment generated 23% of revenue, which was down 3.5% sequentially and up 1.6% from the year-ago quarter. Despite the lower government spending that impacted the environmental and forensics business for yet another quarter, Agilent saw continued strength in chemical, energy and food testing segments across several emerging markets (particularly China).

The recently-added Diagnostics and Genomics segment accounted for 10% of revenue in the last quarter, down 1.8% sequentially. The core business (excluding Dako) was up 6% year over year. Segment revenue stayed 53.8% above the year-ago level. New product launches and expansion in Asia continue but market growth rates remain sluggish, which is a dampener.

Orders

Agilent’s orders were down 5.2% sequentially and 3.7% from the year-ago quarter. The most significant sequential decline was in Life Sciences, although it was still above the year-ago period. Chemical Analysis orders were down 4.4% sequentially but up 4.8% from the year-ago quarter.

Electronic Measurement remained a disappointment, with orders shrinking 3.9% and 16.9%, respectively, from the previous and year-ago quarters. Diagnostics and Genomics orders dropped 5.2% sequentially, staying 50.9% over the year-ago level.

Margins

The pro forma gross margin for the quarter was 54.3%, down 49 basis points (bps) sequentially and up 61 bps from the year-ago quarter. The sequential contraction was related to volume declines in the Electronics Measurement segment and unfavorable mix in the Diagnostics and Genomics segment. The strength in the new Diagnostics segment remains a positive for the overall gross margin, since the segment generates significantly higher gross margins than the legacy Agilent business.

Operating expenses dropped 3.4% sequentially while increasing 3.3% from the year-ago quarter. However, the operating margin shrank 94 bps sequentially and 197 bps year over year to 18.3%, as all expenses increased as a percentage of sales.

The Electronic Measurement operating margin shrank 212 bps sequentially and shrank 491 bps year over year. The Life Sciences margin expanded 165 bps sequentially and 213 bps from the year-ago quarter. The Chemical Analysis margin shrank 75 bps sequentially while expanding 45 bps from last year. The Diagnostics and Genomics margin shrank 214 bps and 37 bps from the year-ago quarter.

Net Income

Agilent generated a pro-forma net income of $233 million or 14.1% net income margin compared to $269 million or 15.5% in the previous quarter and $278 million or 16.1% in the year-ago quarter. Our pro-forma estimate excludes acquisition-related costs, restructuring charges, amortization of intangibles and other one-time items, as well as tax adjustments.

Including these items, the GAAP net income was $168 million ($0.49 per share) compared with income of $166 million ($0.48 cents per share) in the previous quarter and $243 million ($0.69 cents per share) in the year-ago quarter.

Balance Sheet

Inventories were up 1.2% sequentially to $1.05 billion with turns down slightly from 3.0X to 2.9X. The company ended with cash and cash equivalents of $2.33 billion, down $189 million during the quarter. Agilent’s long-term debt was $2.70 billion at quarter-end.

Cash generated from operations was $215 million compared to $315 million generated in the second quarter. Important uses of cash during the quarter included $53 million on capex, $41 million on dividends, $681 million on share repurchases and $250 million for the repayment of senior notes.

Guidance

Agilent provided guidance for the fourth quarter of 2013 and updated the guidance for the year.

In the fourth quarter, Agilent expects revenue of $1.70 billion to $1.72 billion and non-GAAP earnings of 75 to 77 cents a share. Analysts polled by Zacks were expecting earnings of 76 cents, within the guidance.

For fiscal year 2013, Agilent expects revenue of between $6.76 billion and $6.78 billion (previous $6.75 and $6.85 billion). Non-GAAP earnings are expected to be $2.83 to $2.85 a share (previous $2.70 to $2.85).

Recommendation

Agilent’s results were better than expected although the persistent weakness in several end markets because of government sequestration in the U.S., macro weakness in the U.S. and Europe, sluggish semi capex spending, secular decline in PCs and the loss of a major wireless customer remain negatives.

Agilent’s 2013 guidance indicates that the persistent weakness will be offset by cost efficiencies. Earlier the company announced a restructuring initiative that would, after completion, result in a reduction of its workforce by 450 and generate cost savings in the neighborhood of $50 million a year.

While the current outlook for this Zacks Rank #3 (Hold) stock is negative, we remain positive about Agilent’s broader portfolio and diversification into segments with higher growth potential. Further, it continues to introduce new products (with higher margins), which along with those acquired from Dako and Varian have greatly improved its margin profile.

We note that peers Teradyne (TER) and Ametek Inc (AME) also have a Zacks Rank #3, reflecting the difficult market conditions. However, National Instruments Corp (NATI) carries a Zacks Rank #2 (Buy) indicating that this stock would be a safer bet for investors looking for exposure to the segment.

We continue to expect that Agilent, which remains one of the largest providers of spectrum analyzers, network analyzers, signal sources and oscilloscopes to government and research organizations, will see a quick turnaround once market conditions improve.

Read the Full Research Report on A

Read the Full Research Report on AME

Read the Full Research Report on TER

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)

Recommended for You

  • Tycoon buys 30 Rolls-Royces for Macau hotel

    A Hong Kong tycoon has placed the biggest ever order for Rolls-Royce cars, agreeing to buy 30 Phantoms to chauffeur guests at a luxury resort he's building in the global gambling capital of Macau. Stephen Hung's $20 million purchase surpasses the 14 Phantoms bought by Hong Kong's Peninsula Hotel in…

    Associated Press
  • 1 Tip To Lose Belly Fat

    It's Hollywood's Hottest Diet And Gets Rid Of Stubborn Fat Areas Like Nothing Else.

    AdChoicesagoodcooksSponsored
  • Tycoon's arrest sends shock wave through Russia

    Tycoon's arrest sends shock wave through Russia MOSCOW (AP) — The arrest of a Russian telecoms and oil tycoon has sent shock waves through the country's business community, with some fearing a return to the dark days of a decade ago, when the Kremlin asserted its power by imprisoning the country's…

    Associated Press
  • Before You Buy Alibaba, Check Out 4 Top China Stocks

    Before You Buy Alibaba, Check Out 4 Top China Stocks While investors gear up for Alibaba Group 's (BABA) hotly anticipated initial public offering, don't forget about other Chinese stocks that are worth keeping an eye on. Today's Young Guns Screen of

    Investor's Business Daily
  • Play

    Citi, Bank of America Offer Discounted Mortgages

    Citigroup and Bank of America will offer mortgages at discounted interest rates to help borrowers with low incomes or subprime credit. AnnaMaria Andriotis joins MoneyBeat. Photo: Getty.

    WSJ Live
  • As Fed takes baby steps, Cramer's trick for profit

    In turn, Cramer says making money in the market, involves looking at the environment through the lens of the Fed. "The trick is to remember that they speak for the common person," Cramer said. "The Fed wants the common person to make money." With that backdrop always in mind, Cramer says it becomes…

    CNBC
  • "The Retiree Next Door": How successful retirees stretch their savings

    "The Retiree Next Door": How successful retirees stretch their savingsBy the time she hit her late 40s, Toni Eugenia wasn’t sure she would ever be able to retire. Eugenia, 56, a pharmacy technician who lived in Houston, was nearly $200,000 in debt and

    Yahoo Finance
  • Costco Stores in Canada to Stop Taking American Express

    “The credit card relationship between American Express and Costco Wholesale Canada will not be renewed when it expires” on Dec. 31, the company said today in an e-mail to Canadian customers. The message was attributed to Lorelle Gilpin, vice president of marketing and membership for Costco…

    Bloomberg
  • Norwich Information Security MS

    Online, accredited, top ranked. NSA Center of Academic Excellence. Recognized by the Department of Homeland Security. Download your free brochure!

    AdChoicesNorwich UniversitySponsored
  • Beanie Babies creator's sentence debated in court

    Beanie Babies creator's sentence debated in court CHICAGO (AP) — Federal prosecutors seeking to put the billionaire creator of Beanie Babies in prison for hiding millions in Swiss bank accounts told appellate court judges Wednesday that the toymaker's sentence of probation threatens to erode the…

    Associated Press
  • Apple to unveil new iPads, operating system on Oct. 21 : report

    The company plans to unveil the sixth generation of its iPad and the third edition of the iPad mini, as well as its operating system OS X Yosemite, which has undergone a complete visual overhaul, the Internet news website said. Trudy Muller, a spokeswoman for Apple, declined to comment. The iPad is…

    Reuters
  • Gilead Stock Is Falling On These Drug Setbacks

    Gilead Stock Is Falling On These Drug Setbacks Gilead Sciences (GILD) shares are backsliding Wednesday on news that the patient drop-out rate for hepatitis C drug Sovaldi is quadruple that of clinical trials. In addition, the biotech's Phase 2 study results

    Investor's Business Daily
  • CNBC Anchor Calls Out Fed-Hater Bill Fleckenstein In Startling Shouting Match

    CNBC Bill Fleckenstein of Fleckenstein Capital appeared on CNBC's Futures Now program on Tuesday. Futures Now host Jackie DeAngelis came out swinging, asking Fleckenstein right at the top if he was willing to admit that he had misunderstood monetary policy. Sounding taken aback, Fleckenstein…

    Business Insider
  • Don't care about Alibaba? Here's why it may matter

    When the Alibaba Group Holding prices its initial public offering Thursday, small businesses in particular will be watching. Founder Jack Ma -the former English-teacher-turned-dot-com billionaire-has touted his e-commerce platform as a way for smaller merchants to expand their international…

    CNBC
  • Margaritaville casino owners seek bankruptcy

    The owner of Biloxi's Margaritaville casino has filed for Chapter 11 bankruptcy protection Tuesday, only hours before a hearing where the landlord aimed to seize the property. The filing by MVB Holding LLC in U.S. Don Dornan, a lawyer for landlord Clay Point LLC, said the company had planned to ask…

    Associated Press
  • Wondering How You Could Save on Home Insurance?

    Get a quote from Farmers Insurance and discover how you could save. Speak with an agent to get the knowledge you need to make an informed decision.

    AdChoicesFarmers InsuranceSponsored
  • Here's What Mark Cuban Wishes He Knew About Money In His 20s

    Cuban is the owner of the Dallas Mavericks basketball team. Billionaire investor and entrepreneur Mark Cuban is generous with his advice. When we asked him what he wishes he'd known about money in his 20s, he said:

    Business Insider
  • Embraer to sell 50 E-175 jets to Republic in $2.1 billion deal

    Brazil's Embraer SA, the world's third largest commercial planemaker, said on Wednesday it booked a firm order from U.S. The deal, which will be included in Embraer's order book for the third quarter, is valued at $2.1 billion, the planemaker said in a securities filing. The planes will be operated…

    Reuters
  • Play

    Tues., Sept. 16: Watch Humana Stock

    Humana, Global X Social Media Index ETF and Majesco Entertainment are among stocks to watch. WSJ's Chris Dieterich discusses the details with Michael Casey. Photo: Humana

    WSJ Live
  • SHOE COMPANY: Our CEO Just Disappeared And Most Of The Money Is Gone

    "and like that: he's gone." This is an actual headline from a company press release: "CEO and COO disappeared, most of the company's cash missing." (Via FastFT) In a statement, German-based shoe company Ultrasonic said its CFO,  Chi Kwong Clifford Chan, has been unable to reach the company's CEO,…

    Business Insider
  • Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More

    Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More Stocks were firm on Wednesday morning ahead of the FOMC meeting outcome. Tuesday’s rally may have sparked higher interest again, and investors are looking for bargains

    24/7 Wall St.
  • Billionaire Investor Says Chinese People Work Harder And Western Companies Could Face Deep Trouble After Alibaba IPO

    Michael Moritz, the chairman of VC firm Sequoia Capital, is a huge fan of Chinese internet companies and reiterated his enthusiasm for the Chinese market in an interview with The Wall Street Journal Wednesday. The billionaire investor described the Alibaba IPO as a “major landmark event” that is as…

    Business Insider
  • Best Womens Wrinkle Creams 2014

    Mom reveals simple wrinkle solution that has researchers very excited. Try this free solution today to look and feel years younger.

    AdChoicesBellaLabs.comSponsored
  • Don't buy Alibaba stock: 'Dean of Valuation'

    Investors should steer clear of Alibaba , valuation expert Aswath Damodaran said Wednesday. On CNBC's " Fast Money ," Damodaran, a professor of finance at New York University's Stern School of Business, noted that he was looking at Alibaba stock from the perspective of a long-term investor, not a…

    CNBC